Navigation Links
A Blood Sample Predicts if Cancer Patients Respond to Therapy
Date:5/2/2013

STOCKHOLM, May 2, 2013 /PRNewswire/ --

Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy, how long treatment will be effective and survival. The results are being presented at the IMPAKT scientific conference in Brussels, May 2-4. The analysis measures growth rate and this is the first time ever that one test have documented this by analysing a blood sample.

     (Photo: http://photos.prnewswire.com/prnh/20130502/612873 )

The study (called TEX) included 287 women with breast cancer who were treated with two different kinds of chemotherapy. The test, DiviTum™, analyses cell-division rate in blood taken from patients before treatment initiation. Regardless of therapy, DiviTum™ predicted which groups of patients who would respond to treatment or not. Patients with tumours that expressed a low DiviTum™-value lived significantly longer, 38 months, compared to 21 months for those with high values.

"By analysing the growth rate in a blood sample we can receive new, valuable clinical information on patient risk and ability to respond to treatment. With DiviTum™ there is an opportunity to identify patients who are at high risk for progression, and this group possibly requires more intense or different treatment", says Thomas Hatschek , lead investigator for the study and Associate Professor at Karolinska Institutet.

"We are keen to look at more possibilities to use DiviTum™ and we will test whether the technology also can be used initially, after starting therapy, to predict and monitor the effect of a chosen treatment. This would at an early stage be a tool to determine whether treatment is appropriate or not. The fact that it only takes a blood sample is an advantage because other methods require tumour tissue", says Thomas Hatschek .

 "We look forward to continued collaboration with Karolinska Institutet, contributing to improved diagnostics and monitoring of cancer patients. It's very positive that the information DiviTum™ provides can give a more comprehensive picture of the disease", says Anders Rylander , CEO Biovica.

Biovica is a bio-diagnostic company, founded in 2009 and ISO 13485 certified for Quality Management Systems. DiviTum™ is CE labelled and MPA registered.
See also http://www.biovica.com


For more information:
Thomas Hatschek , Associate Professor at Radiumhemmet, Karolinska University Hospital & Karolinska Institutet, Department of Oncology-pathology.
Mobile phone: + 46-(0)709-24-43-41      
e-mail: thomas.hatschek@karolinska.se

Anders Rylander , CEO Biovica.
Mobile phone: +46-(0)761-61-21-90    
e-mail: anders.rylander@biovica.com



'/>"/>
SOURCE Biovica International AB
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. FindTheBest Helps Parents Find Cord Blood Banks
2. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
5. Study finds chronic abnormal brain blood flow in Gulf War veterans
6. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
7. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
8. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
9. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
10. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
11. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):